FLGT
Get informed when a big investor buys or sells
+ FollowOvervalued by 59.5% based on the discounted cash flow analysis.
| Market cap | $543.59 Million |
|---|---|
| Enterprise Value | $657.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.97 |
| Beta | 0.89 |
| Outstanding Shares | 28,005,000 |
| P/E Ratio | -6.79 |
|---|---|
| PEG | -12.17 |
| Price to Sales | 1.7 |
| Price to Book Ratio | 0.53 |
| Enterprise Value to Revenue | 2.03 |
| Enterprise Value to EBIT | -6.46 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.14 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 41.54% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 12.31%▼ 44.39% |
|---|---|
| Total Invested | $78.03M▼ 71.88% |
| Investors Holding | 46▼ 115.00% |
No data
Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and...